Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type?2 diabetes.

ABSTRACT: Aims/Introduction:? We compared the safety and efficacy of liraglutide vs glibenclamide in patients with poorly controlled (HbA1c, 7.4-10.4%) type?2 diabetes.? Subjects were randomly assigned at a 1:2 ratio to receive 1-year treatment with glibenclamide 1.25-2.5?mg/day or liraglutide 0.9?mg/day. Other oral anti-diabetic drugs (OAD) were prohibited during the trial. Adverse events (AE) were monitored.? A total of 400 patients (liraglutide group, n?=?268; glibenclamide group, n?=?132) were randomized and exposed to trial products. At week?52 vs baseline, HbA1c in the liraglutide and glibenclamide groups was reduced from 9.3 to 7.8% and from 9.2 to 8.2%, respectively. Treatment difference (liraglutide?-?glibenclamide) at the end of the study was -0.49 (95% CI, -0.71 to -0.27). In the liraglutide and glibenclamide groups, Japan Diabetes Society target HbA1c?

SUBMITTER: Kaku K 

PROVIDER: S-EPMC4014903 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature